Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Scientists at University of Texas target immunotherapy
May 28th, 2008
"The ultimate success of dendritic cell (DC) vaccination for the active immunotherapy of neoplasia is thought to be dependent on a very large number of variables, including DC generation protocol, loading methodology, dose, route of administration, and maturation method. Although the use of a maturation cocktail comprising interleukin (IL)-1 beta, tumor necrosis factor-alpha, IL-6, and prostaglandin E-2 (ITIP) has recently appeared in the literature, much of the data in the basic and clinical literature have been generated using DCs matured with the single inflammatory cytokine TNF-alpha," investigators in the United States report. "Here, we demonstrate that DCs matured...
Source: Vaccine Weekly (2008-05-28)
|
